Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Imunon, Inc. stock logo
IMNN
Imunon
$2.67
+34.1%
$0.95
$0.37
$3.65
$46.83M1.753.37 million shs32.60 million shs
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
$1.35
+0.7%
$1.08
$0.51
$5.01
$22.84M1.932.19 million shs106,085 shs
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$3.36
-0.1%
$3.11
$2.57
$6.88
$20.73M0.599,047 shs16,911 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$3.44
+2.1%
$2.90
$1.75
$9.37
$5.56M1.66829,454 shs151,882 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Imunon, Inc. stock logo
IMNN
Imunon
+34.15%+130.13%+217.80%+199.71%+81.60%
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
+0.75%+10.66%+16.38%+35.00%+53.60%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-0.15%+0.15%+11.83%-18.17%-49.32%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
+2.08%+7.17%-9.47%+51.54%+1,223.08%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Imunon, Inc. stock logo
IMNN
Imunon
1.8354 of 5 stars
3.42.00.00.03.00.00.6
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
2.866 of 5 stars
3.75.00.00.02.80.00.6
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
1.103 of 5 stars
0.03.00.00.03.31.70.6
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.7321 of 5 stars
0.05.00.00.02.80.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Imunon, Inc. stock logo
IMNN
Imunon
2.75
Moderate Buy$15.50480.63% Upside
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
3.33
Buy$14.00937.04% Upside
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.00
N/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SNOA, NAII, MIRA, and IMNN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/19/2025
Imunon, Inc. stock logo
IMNN
Imunon
D Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/19/2025
Imunon, Inc. stock logo
IMNN
Imunon
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold
5/13/2025
Imunon, Inc. stock logo
IMNN
Imunon
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$29.00 ➝ $17.00
5/7/2025
Imunon, Inc. stock logo
IMNN
Imunon
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
3/26/2025
Imunon, Inc. stock logo
IMNN
Imunon
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
3/24/2025
Imunon, Inc. stock logo
IMNN
Imunon
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$29.00 ➝ $29.00
(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Imunon, Inc. stock logo
IMNN
Imunon
$500K93.66N/AN/A$1.42 per share1.88
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/AN/AN/AN/A$0.30 per shareN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
$125.48M0.17N/AN/A$12.77 per share0.26
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$13.97M0.40N/AN/A$3.01 per share1.14
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Imunon, Inc. stock logo
IMNN
Imunon
-$19.51M-$1.36N/AN/AN/AN/A-230.05%-128.98%8/13/2025 (Estimated)
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-$11.98M-$0.51N/AN/AN/AN/A-337.44%-280.58%8/12/2025 (Estimated)
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
-$7.22M-$1.39N/AN/A-6.26%-9.36%-4.82%N/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$4.84M-$4.02N/AN/AN/A-26.82%-68.98%-26.39%6/16/2025 (Estimated)

Latest SNOA, NAII, MIRA, and IMNN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2025Q1 2025
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-$0.15-$0.11+$0.04-$0.11N/AN/A
5/14/2025Q3 2025
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/A-$0.37N/A-$0.37N/A$28.77 million
5/12/2025Q1 2025
Imunon, Inc. stock logo
IMNN
Imunon
-$0.35-$0.28+$0.07-$0.28N/AN/A
3/28/2025Q4 2024
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
-$0.29-$0.15+$0.14-$0.15N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Imunon, Inc. stock logo
IMNN
Imunon
N/AN/AN/AN/AN/A
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/AN/AN/AN/AN/A
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Imunon, Inc. stock logo
IMNN
Imunon
N/A
2.30
2.30
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
N/A
6.11
6.11
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
0.11
2.70
1.50
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
3.34
2.49

Institutional Ownership

CompanyInstitutional Ownership
Imunon, Inc. stock logo
IMNN
Imunon
4.47%
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
35.16%
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
32.40%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.95%
CompanyEmployeesShares OutstandingFree FloatOptionable
Imunon, Inc. stock logo
IMNN
Imunon
3017.54 million13.78 millionNot Optionable
MIRA Pharmaceuticals, Inc. stock logo
MIRA
MIRA Pharmaceuticals
216.92 million15.46 millionNot Optionable
Natural Alternatives International, Inc. stock logo
NAII
Natural Alternatives International
2906.18 million4.90 millionNot Optionable
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1801.62 million1.55 millionNot Optionable

Recent News About These Companies

Sonoma Pharmaceuticals expands into UK market
Sonoma Pharmaceuticals, Inc. (O8Z.F)
Sonoma Pharmaceuticals announces relaunch of dermatology, eye care lines

New MarketBeat Followers Over Time

Media Sentiment Over Time

Imunon stock logo

Imunon NASDAQ:IMNN

$2.67 +0.68 (+34.15%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$2.74 +0.07 (+2.60%)
As of 05/30/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

MIRA Pharmaceuticals stock logo

MIRA Pharmaceuticals NASDAQ:MIRA

$1.35 +0.01 (+0.75%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$1.33 -0.02 (-1.56%)
As of 05/30/2025 06:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder. In addition, its oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is headquartered in Miami, Florida.

Natural Alternatives International stock logo

Natural Alternatives International NASDAQ:NAII

$3.36 -0.01 (-0.15%)
As of 05/30/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Natural Alternatives International, Inc. engages in formulating, manufacturing, and marketing nutritional supplements in the United States, Europe, Australia, Asia, Mexico, and Canada. The company operates in two segments, Private-Label Contract Manufacturing, and Patent and Trademark Licensing. It offers private-label contract manufacturing services to companies that market and distribute vitamins, minerals, herbal, and other nutritional supplements, as well as other health care products. The company also provides strategic partnering services, such as customized product formulation, clinical study design and support, manufacturing, marketing support, international regulatory and label law compliance, international product registration, packaging in multiple formats and labeling design, scientific research, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management, packaging and delivery system design, regulatory review, and international product registration assistance. In addition, it sells beta-alanine ingredient under the CarnoSyn and SR CarnoSyn names. The company manufactures products in various forms, including capsules, tablets, chewable wafers, and powders. Its private-label contract manufacturing customers include companies that market nutritional supplements through direct sales marketing channels, direct to consumer e-commerce channels, and retail stores. The company was founded in 1980 and is headquartered in Carlsbad, California.

Sonoma Pharmaceuticals stock logo

Sonoma Pharmaceuticals NASDAQ:SNOA

$3.44 +0.07 (+2.08%)
Closing price 05/30/2025 04:00 PM Eastern
Extended Trading
$3.47 +0.03 (+0.87%)
As of 05/30/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.